Search results
Surprising Health Conditions Our Favorite Celebs Struggle With
Cheapism via AOL· 8 hours agoBruce Glikas/Getty Images CC Kim Kardashian-West Condition: Psoriasis With so much of her career...
Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimates with Strategic Collaborations
GuruFocus.com via Yahoo Finance· 1 day agoThis positions JNJ-2113, a novel oral IL-23 receptor antagonist, as a potential leader in psoriasis ...
The best face wash for sensitive skin in 2024 will leave your face fresh, clean and never angry
Yahoo Life Shopping· 5 days agoWhile certain skin conditions fall within the sensitive skin territory, such as eczema, rosacea and ...
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
InvestorPlace· 2 days agoInvestors concerned about broader market undulations may want to consider the resilience narrative...
Teva Pharm to launch Humira biosimilar as Q1 profit misses estimates
Reuters· 15 hours ago, opens new tab blockbuster arthritis drug Humira in the coming weeks after it posted mixed results in the first three months of 2024. In the wake of February's U.S. Food and Drug Administration ...
Protagonist Reports First Quarter 2024 Financial Results and Provides Corporate Update
Morningstar· 1 day agoEntered into a worldwide license and collaboration agreement for rusfertide with Takeda; Cash runway extended through Q4 2027[1]Enrollment in both Phase 3 ICONIC LEAD and ICONIC TOTAL trials ...
Where Is Amgen Headed After the Stock Surges on Obesity Drug News?
TheStreet.com· 6 days agoThe company also "tweaked" their forward guidance and the stock was raised to a fundamental...
Immunic advances ‘potentially groundbreaking’ MS therapy vidofludimus calcium during Q1
Proactive Investors· 22 hours agoImmunic Inc (NASDAQ:IMUX) continued to advance its clinical programs for its lead drug asset,...
Protagonist Therapeutics Inc (PTGX) Surpasses Q1 Revenue Estimat
Guru Focus· 1 day agoOn May 7, 2024, Protagonist Therapeutics Inc (PTGX, Financial) unveiled its financial outcomes for the first quarter ended March 31, 2024, through its 8-K filing. The clinical-stage biopharmaceutical ...
2 Magnificent Dividend Stocks to Hold for the Next Decade
Motley Fool via Yahoo Finance· 4 days agoHowever, one of Novartis' most important products, psoriasis treatment Cosentyx, will run out of...